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Abstract
Background: Vaginal pH is related to genital tract inflammation and changes in the bacterial flora, both suggested
cofactors for persistence of human papillomavirus (HPV) infection. To evaluate the relationship between vaginal pH
and HPV, we analyzed data from our large population-based study in Guanacaste, Costa Rica. We examined vaginal
pH and the risk of HPV infection, cytological abnormalities, and C. trachomatis infection.
Methods: Our study included 9,165 women aged 18-97 at enrollment with a total of 28,915 visits (mean length of
follow-up = 3.4 years). Generalized estimating equations were used to evaluate the relationship between vaginal
pH and HPV infection (both overall and single versus multiple types) and low-grade squamous intraepithelial
lesions (LSIL), the cytomorphic manifestation of HPV infection. The relationship between enrollment vaginal pH and
C. trachomatis infection was assessed by logistic regression. Results were stratified by age at visit.
Results: Detection of HPV was positively associated with vaginal pH, mainly in women < 35 years (p-trend = 0.009
and 0.007 for women aged < 25 and 25-34 years, respectively). Elevated vaginal pH was associated with 30%
greater risk of infection with multiple HPV types and with LSIL, predominantly in women younger than 35 and 65+
years of age. Detection of C. trachomatis DNA was associated with increased vaginal pH in women < 25 years (OR
2.2 95% CI 1.0-5.0).
Conclusions: Our findings suggest a possible association of the cervical microenvironment as a modifier of HPV
natural history in the development of cervical precancer and cancer. Future research should include studies of
vaginal pH in a more complex assessment of hormonal changes and the cervicovaginal microbiome as they relate
to the natural history of cervical neoplasia.
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Background
The development of cervical cancer is linked to persis-
tent infection with at least one of about a dozen carci-
nogenic genotypes of human papillomavirus (HPV)[1].
Most HPV infections are transient [2] and only a small
minority of women with long-term, persistent infections
are at an increased risk of progression to precancerous
cervical lesions and cervical cancer [2,3]. Although this
causal role is well established, relatively little is known
about non-behavioral factors that influence risk of HPV
acquisition and persistence. Alterations in the vaginal
microenvironment, due to vaginal douching [4], bacter-
ial vaginosis (BV) [5], and sexually transmitted infections
[6,7] have been implicated as cofactors for persistence of
HPV infection. Although the mechanisms for these
associations, if ultimately confirmed, are not completely
understood, factors relating to the vaginal microenviron-
ment such as an acidic vaginal pH and the presence of
Lactobacilli are key components of the vaginal defense
system [8]. Changes in vaginal microflora such as bac-
terial vaginosis, and vaginal infections are usually
accompanied by increases in pH [9,10] while acidic
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trachomatis, trichomoniasis [11], urinary tract infections
[12], and mycoplasma [11]. Therefore, it is conceivable
that vaginal pH could be associated with HPV preva-
lence, through unknown direct or indirect mechanisms
affecting acquisition or persistence.
Vaginal pH reflects a combination of factors affecting
the vaginal microenvironment. In healthy, reproductive
aged women, vaginal pH is primarily determined by the
lactic acid produced by the metabolically active epithe-
lium and from Lactobacillus species that dominate the
vaginal microflora and produce lactic acid from anaero-
bic glycolysis [8]. Both processes are fueled by glucose
which is stored as glycogen in the vaginal mucosal cells
[8]. A pH range of 4.0-4.5 is considered normal for pre-
menopausal women [13]. After menopause the pH
increases, as circulating estrogens decline and cause a
depletion of glycogen and glucose metabolism, and a
loss of Lactobacilli in the vaginal mucosa [8]. It has
been theorized that this rise in vaginal pH is associated
with a loss of natural epithelial defenses and an
increased rate of colonization with pathogens in the
vagina and the urinary tract [14].
Our study examined the relationship between vaginal
pH and risk of HPV infection and HPV-related cytologi-
cal abnormalities, with particular attention to possible
differences between women in varying age groups in a
large screening study of HPV infection and cervical neo-
plasia in Guanacaste Province, Costa Rica. In addition,
we evaluated whether there is an association between
increased vaginal pH and C. trachomatis DNA measured
from cervical cells obtained in a random subset of
cohort members at enrollment.
Methods
Study population
Vaginal pH was measured during enrollment and fol-
low-up screening visits of a population-based cohort
study of cervical neoplasia in Guanacaste, Costa Rica.
Detailed methods of recruitment, screening, and follow-
up have been reported elsewhere [15,16]. Briefly, a ran-
dom sample of about 20% of Guanacaste census tracts
identified 11,742 women, of whom 10,769 were eligible
for the study (Figure 1). Of these eligible women, 10,049
agreed to participate and were interviewed after giving
informed consent. A pelvic examination was offered to
women who reported previous sexual intercourse in the
interview and of the 9,466 eligible, 9,175 (97%) had the
exam performed. At enrollment, vaginal pH measure-
ments were obtained from 9,165 women. A subcohort
of women (n = 3,065) who were at risk of developing
CIN3 or cancer (CIN3+) based on enrollment screening
results and reported sexual behavior, as well as a group
of women who had negative screening results (referent
group) were actively followed at intervals of 6 or 12
months for up to 7 years. The remaining 6,029 women,
who were considered (and subsequently proven) to be at
very low risk of cervical cancer based on completely
negative multimodal screening, were included in the
p a s s i v ef o l l o w - u pc o h o r tt h a tw a ss c r e e n e da g a i na t5 - 7
years after enrollment [16]. Among the 9,094 women
followed, 8,080 (88.8%) had at least one follow-up visit.
Of the active cohort, 87.4% had greater than one follow
up visit whereas 98% of the passive cohort had at least
one follow up visit. The median follow-up times in both
cohorts were equivalent (6-7 years), although the screen-
ing intensity was clearly higher in the active cohort. The
study protocol was reviewed and reapproved annually by
the National Cancer Institute and a Costa Rican Institu-
tional Review Board.
Specimen collection
Exfoliated cervical cells for split-sample conventional
Pap smear and ThinPrep cytology (Cytyc Corp., Boxbor-
ough, MA) were collected using a Cervex broom-like
collection device (Unimar, Wilton, CT) during the pelvic
exam. Additional cervical cells were collected using a
Dacron swab and stored in Specimen Transport med-
ium (Qiagen, previously Digene Corp., Gaithersburg,
MD) for HPV testing. Cervical abnormalities were iden-
tified by visual inspection, cytology, or cervicography.
Cervical cytologic abnormalities were classified as cancer
and/or high-grade squamous intraepithelial lesions
(HSIL+), low-grade squamous intraepithelial lesions
(LSIL), atypical squamous cells of undetermined signifi-
cance (ASCUS), reactive changes, or normal. As the cur-
rent analysis focused on HPV-related cytomorphologic
changes, a woman’s cytology was interpreted as LSIL if
her conventional smear and/or ThinPrep results met the
criteria for LSIL and the diagnosis of the alternative
method was either ASCUS or LSIL.
HPV determination by polymerase chain reaction
Specimens from the enrollment visit were tested initially
in the United States by the Hybrid Capture Tube test
(Qiagen, previously Digene Corp., Gaithersburg, MD).
However, because this method had limited sensitivity
(10 pg/mL) and only detected 11 of the carcinogenic
HPV types, all specimens were retested using a polymer-
ase chain reaction (PCR) test. As previously described
[17,18], DNA extracted from exfoliated cells in a 100-μL
aliquot of the specimen was amplified using the MY09/
MY11 L1 degenerate primer PCR system with AmpliTaq
Gold polymerase (TaqGold; Perkin-Elmer-Cetus, Nor-
walk, CT). After amplification, PCR products were ana-
lyzed by electrophoresis and hybridized with
radiolabeled generic HPV DNA probes. Type specific
oligonucleotide hybridization was used for HPV typing:
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35, 39, 40, 42-45, 51-59, 61, 62, 64, 66-74, 81-85, and 89.
We considered the following HPV types as carcinogenic:
HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59
[19]. The HPV testing lab was masked to clinical out-
comes. All PCR testing and genotyping were done in
the United States, at the Albert Einstein College of
Medicine in New York.
Vaginal pH measurements
Vaginal pH was measured with a pHydrion strip (Micro
Essential Laboratories, Brooklyn, NY). After insertion of
a sterile speculum the pHydrion strip was placed on the
left lateral vaginal wall between the speculum blades
until moistened and color change was immediately com-
pared with the colorimetric scale and the measurement
was recorded across a range of 3.0-5.5 in increments of
0.5 pH units.
Detection of C. trachomatis DNA
Detection of C. trachomatis was measured with an assay
for C. trachomatis DNA as previously described [20] in
an age-stratified subsample (N = 1,216). Briefly, C. tra-
chomatis DNA was detected in enrollment samples
using a C. trachomatis PCR-DEIA assay (Labo Biomedi-
cal Products BV, Rijswijk, the Netherlands). After the
PCR, C. trachomatis DNA was detected by C. trachoma-
tis–specific probe hybridization in a DNA enzyme
immunoassay that used 10 μL of the PCR product. The
mixture of probes present in the C. trachomatis DNA
enzyme immunoassay can recognize all C. trachomatis
serovars and genovariants that have been deposited in
GenBank.
Statistical analysis
The unit of analysis was the study visit. Based on their
age at each visit, women were stratified into the follow-
ing categories: < 25 years, 25-34 years, 35-44 years, 45-
54 years, 55-64 years and 65+ years. To standardize fre-
quency of visits by time, each clinic visit was assigned to
a bin defined by years after enrollment. Bins for each
woman began with bin 0 (enrollment date), continued
for every year until they were censored (for suspicion of
HSIL+ or completion of the follow-up, i.e., at least 6
 Randomsampleofabout20%of
Guanacastecensustracts
(n=11,742)
10,769womenmeteligibilitycriteria
10,049womenconsentedtoparticipate
9,175women(97%)receivedpelvicexam
9,165womentestedforvaginalpHat
enrollment
3,065womenactivelyfollowedevery6Ͳ12
monthsforupto7years,87.45%hadgreater
thanonefollowupvisit(totalof16,420visits)
6,029womenwerepassivelyfollowedandreͲ
screenedevery5Ͳ7years,98%hadatleast
onefollowupvisit(totalof12,495visits)
Figure 1 Consort diagram.
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Page 3 of 9years and 9 months from enrollment) or they were lost
to follow-up. If a woman was tested more than once in
a bin and her HPV results were discordant on positivity,
the result from the positive visit was taken to acknowl-
edge the possibility of HPV measurement error. Simi-
larly, if pH was tested more than once in a bin, the visit
with the highest vaginal pH recorded was chosen.
Regarding cytology, if more than one result was avail-
able, the more severe reading was chosen.
Our main analyses focused on risk of HPV positivity
with vaginal pH as the primary independent variable.
We calculated the odds of testing HPV positive vs. test-
ing negative and the odds of testing positive for multiple
HPV types vs. a single HPV type. For all of the above-
mentioned analyses, we used the method of generalized
estimating equations (GEE) with an independent corre-
lation structure [21]. This approach accounted for
repeated visits resulting in possible auto-correlation and
reduced overall variance, but it made few assumptions
regarding the nature of the intra-individual correlations
[22]. To determine if elevated vaginal pH was also
related to HPV-induced cytological abnormalities, we
calculated the odds of concurrent LSIL cytology, vs. a
result of normal or reactive changes and we looked at
the relationship between vaginal pH and high grade
lesions(HSIL) compared to ≤ LSIL among HPV positive
women.
When appropriate to increase statistical power and
stability of estimates, we included vaginal pH as a
dichotomous variable (pH < 5.0 and pH ≥ 5.0). We used
logistic regression to examine the association between
vaginal pH and C. trachomatis at enrollment. Analyses
were performed using Stata 11.0 analytic software (Stata
Corp LP, College Station, TX).
Results
Nine thousand one hundred sixty-five women were
included in this study, with a total of 28,915 visit data
points. Overall, the mean age at the time of visit was
41.8 ± 15 years (range 18-100 years).
Ordinal logistic regression analysis revealed a signifi-
cant relationship between vaginal pH and age at visit
(OR 1.6 95% CI 1.6-1.6). Figure 2 shows the percentage
of women with a given pH measurement for each age
group at the time of visit. The majority of women
younger than 45 (age groups < 25 years, 25-34 years,
and 35-44 years) had a pH of 4.5 (~68% for each age
group) while a relatively low percentage had a pH of 5.5
(~3.0%). On the other hand, almost half of the women
55 and older (age groups 55-64 years and 65+ years)
had a pH of at least 5.0 and a relatively higher percen-
tage of these age groups compared to younger women
had a pH of 5.5 (~16% and 21% for women 55-64 and
65+ years, respectively).
Figure 2 The percentage of women with a given pH measurement (4.0, 4.5, 5.0, or 5.5) stratified by age at visit.
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age group and decreased somewhat steadily among the
older age groups, with a slight increase in women aged
65+ years in all visit data (data not shown).
Detection of HPV was positively associated with vagi-
nal pH in women in all age groups under age 55 with
about a 10-20% increased risk of HPV detection for a
vaginal pH ≥ 5 (Table 1). At the post-menopausal age
ranges (55-64, and 65+ years, respectively), there were
no significant associations between vaginal pH and
detection of HPV. The data were underpowered to con-
duct a type-specific analysis; however, we assessed at the
association between vaginal pH and a pool of 12 carci-
nogenic HPV types. The results were similar to those in
Table 1 with the exception of women aged 65+, who
showed a stronger, significant association between a
vaginal pH > 5.0 and carcinogenic HPV positivity (GEE
OR 1.6 95% CI 1.1-2.3).
A similar positive association was found between ele-
vated vaginal pH (5.0-5.5) and detection of more than
Table 1 Risk of testing PCR positive for HPV at each visit given vaginal pH measurement, stratified by age at visit
Vaginal pH Level N Percent with PCR Positive HPV Odds of Testing HPV Positive
a (95% CI) p-value (trend)
All Women
b
4.0 2,139 19.1 0.7 (0.7-0.8)
4.5 17,201 23.8 ref
c
5.0 7,246 25.6 1.2 (1.1-1.3)
5.5 1,976 25.2 1.2 (1.1-1.4) < 0.001
Age at Visit
< 25 years
4.0 114 22.8 0.5 (0.3-0.8)
4.5 1,417 38.3 ref
5.0 404 40.8 1.1 (0.9-1.4) 0.009
5.5 82 41.5 1.1 (0.7-1.8)
25-34 years
4.0 798 22.7 0.8 (0.7-1.0)
4.5 5,436 26.5 ref
5.0 1,517 29.8 1.2 (1.0-1.3)
5.5 240 29.2 1.1 (0.9-1.5) 0.007
35-44 years
4.0 842 17.5 0.9 (0.7-1.1)
4.5 5,244 19.6 ref
5.0 1,407 21.4 1.1 (1.0-1.3)
5.5 194 16.0 0.8 (0.5-1.1) 0.088
45-54 years
4.0 310 13.6 0.8 (0.5-1.1)
4.5 2,912 17.2 ref
5.0 1,432 19.8 1.2 (1.0-1.4)
5.5 372 18.0 1.1 (0.8-1.4) 0.051
55-64 years
4.0 48 12.5 0.4 (0.2-1.0)
4.5 1,253 25.1 ref
5.0 1,194 23.3 0.9 (0.7-1.1)
5.5 481 23.9 0.9 (0.7-1.2) 0.209
65+ years
4.0 27 22.2 0.7 (0.3-1.9)
4.5 939 27.7 ref
5.0 1,292 29.1 1.1 (0.9-1.3)
5.5 607 29.7 1.1 (0.8-1.4) 0.773
a Generalized estimating equation models with an independent correlation structure were used to estimate the odds of testing positive for HPV given pH
measurements at each visit
b Adjusted for age at visit
c A pH of 4.5 was used as the referent category because it provided the most stable comparison
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negative) (GEE OR 1.3; 95% CI 1.1-1.4) when adjusted
for age at visit (Table 2). Age-stratified analyses revealed
significant, positive associations between vaginal pH and
detection of multiple HPV types vs. infection with a sin-
gle type in women aged < 25 and 25-34 years as they
were 50% and 30% more likely to have a multiple infec-
tions, respectively. This relationship was also significant
among women aged 65+ years (GEE OR 1.6; 95% CI
1.1-2.2).
When adjusted for age at visit, a vaginal pH of ≥ 5.0
was positively associated with a diagnosis of LSIL vs.
normal cytology including reactive changes (GEE OR
1.3; 95% CI 1.1-1.6) (Table 3). This positive relation-
ship was present in all age groups, and was significant
in women < 25 and 25-34 years of age (GEE OR 1.5
95% CI 0.9-2.3; GEE OR 1.4 95% CI 1.0-1.9, respec-
tively) and in women 65+ years of age (GEE OR 2.7
95% CI 1.0-7.0).
To examine the question of whether elevated pH
might be associated with progression to precancer
among HPV infected women, we restricted our analyses
to HPV positive women but found no association
between HSIL and elevated pH (data not shown).
To assess whether vaginal pH could reflect (or pre-
dict) the presence of other sexually transmitted infec-
tions, we analyzed the relationship between the presence
of C. trachomatis DNA detected in cervical exfoliated
cells and vaginal pH at enrollment in the subgroup of
women previously described. Among women < 25 years,
we found a positive association between vaginal pH and
presence of C. trachomatis DNA (OR 2.2 95% CI 1.0-
5.0), with women with a pH of > 5.0 (n = 37) more
likely to have a C. trachomatis infection (32.4%) versus
women with a pH of < 5.0 (n = 135), of whom only
17.8% were positive (data not shown). This positive rela-
tionship was present among women younger than 45
years, however in women aged 45+, an inverse trend
was observed, though these results were not significant.
Discussion
We report a positive association between vaginal pH
and HPV positivity in a veryl a r g ec o h o r to fr a n d o m l y
selected women. The relationship between HPV and
vaginal pH was particularly pronounced in pre-meno-
pausal women (< 25 and 25-34 years). The presence of
multiple HPV type infections was also significantly
related to elevated vaginal pH overall and particularly in
Table 2 Risk of testing PCR positive for multiple HPV types at each visit given vaginal pH measurement, stratified by
age at visit
Vaginal pH Level N Percent with Multiple HPV Types Odds of Testing PCR Positive for Multiple HPV Types
a (95% CI) p-value
All Women
b
4.0-4.5 4,118 35.1 ref < 0.01
5.0-5.5 2,165 39.4 1.4 (1.1-1.4)
Age at Visit
< 25 years
4.0-4.5 535 46.2 ref 0.01
5.0-5.5 187 56.7 1.5 (1.1-2.1)
25-34 years
4.0-4.5 1,501 34.6 ref 0.01
5.0-5.5 483 41.2 1.3 (1.1-1.6)
35-44 years
4.0-4.5 1,053 30.4 ref 0.42
5.0-5.5 307 32.9 1.1 (0.8-1.5)
45-54 years
4.0-4.5 492 32.1 ref 0.48
5.0-5.5 314 29.6 0.9 (0.6-1.2)
55-64 years
4.0-4.5 297 38.7 ref 0.16
5.0-5.5 365 32.9 0.8 (0.5-1.1)
65+ years
4.0-4.5 240 35.0 ref < 0.01
5.0-5.5 509 46.0 1.6 (1.1-2.2)
a Generalized estimating equation models with an independent correlation structure were used to estimate the odds of testing positive for multiple HPV given
dichotomous pH measurements at each visit
b Adjusted for age at visit
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line with these results, we also found a significant posi-
tive association between increased vaginal pH and LSIL,
a cytomorphic indicator of HPV infection. This relation-
ship was particularly significant in the youngest (< 25
and 25-34 years) and the oldest (65+ years) age groups.
Our study confirmed that vaginal pH rises with age,
starting in the peri-menopausal age range. These results
are in line with a previous cross-sectional study evaluat-
ing the epidemiologic determinants of vaginal pH in the
same-population based sample from Guanacaste (enroll-
ment data only) in which vaginal pH was strongly
related to age and menopausal status [23]. However the
authors did not find an association between elevated pH
and HPV infection (11 carcinogenic types) in the base-
line data [23].
HPV is a sexually transmitted infection and the asso-
ciation of HPV prevalence with elevated vaginal pH
could be due to some unmeasured aspect of sexual
behavior. However, changes in the vaginal microenvir-
onment associated with pH in younger women affect
the immunological balance within the cervical tissue
and provide a biologically plausible mechanism for
increased HPV prevalence [24,25]. A healthy vaginal
microflora in women of reproductive age maintain a low
vaginal pH (< 4.5) [8]. A high vaginal pH is indicative of
changes within the vaginal microflora and is used as a
criterion in the diagnosis of BV [8] in which several
types of anaerobic bacteria, such as Gardernella vagina-
lis, predominate in the vaginal cavity [26]. The absence
of protective lactobacilli and an increased vaginal pH
has been shown to increase susceptibility for sexually
transmitted infections, and thus t could possibly be
associated with elevated risk of HPV acquisition [5].
Interestingly, we also found a positive relationship
between C. trachomatis DNA and vaginal pH among
women < 25 years. Previous in vitro studies have
demonstrated a significant reduction of C. trachomatis
replication when exposed to acidic pH [11,27] and a
prospective case-control study [28] found that C. tracho-
matis infection was associated with higher vaginal pH
even when controlling for BV. Taken altogether, these
findings suggest a common link between increased vagi-
nal pH and susceptibility to acquiring sexually trans-
mitted infections, and warrant further exploration.
Although the relationship between elevated vaginal pH
and overall HPV positivity was not significant among
women aged 65+ years, we did find a positive
Table 3 Risk of low-grade squamous intraepithelial neoplasia (LSIL) diagnosis at each visit given vaginal pH
measurement, stratified by age at visit
Vaginal pH Level N Percent with LSIL Odds of LSIL Cytology
a (95% CI) p-value
All Women
b
4.0-4.5 19,272 2.4 ref < 0.01
5.0-5.5 9,059 2.5 1.3 (1.1-1.6)
Age at Visit
< 25 years
4.0-4.5 1,536 4.0 ref 0.12
5.0-5.5 475 5.7 1.5 (0.9-2.3)
25-34 years
4.0-4.5 6,178 2.9 ref 0.02
5.0-5.5 1,721 4.0 1.4 (1.0-1.9)
35-44 years
4.0-4.5 6,074 2.3 ref 0.30
5.0-5.5 1,568 2.8 1.2 (0.9-1.7)
45-54 years
4.0-4.5 3,216 1.9 ref 0.33
5.0-5.5 1,776 2.3 1.2 (0.8-1.8)
55-64 years
4.0-4.5 1,308 1.3 ref 0.82
5.0-5.5 1,653 1.4 1.1 (0.6-1.9)
65+ years
4.0-4.5 960 0.5 ref 0.04
5.0-5.5 1,866 1.4 2.7 (1.0-7.0)
a Generalized estimating equation models with an independent correlation structure were used to estimate the odds of testing positive LSIL given dichotomous
pH measurements at each visit
b Adjusted for age at visit
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carcinogenic HPV, multiple HPV type infections, and
diagnosis of LSIL in these women. Risk of HPV infec-
tion may be exacerbated by an age-related attenuation
of the immune response and reductions of the natural
immune defenses of the skin, typical of menopause [29].
The vaginal pH is known to increase after menopause,
as circulating estrogens decline and cause a depletion of
glycogen and glucose metabolism [8]. Our findings
among post-menopausal women may draw a link
between the decline in circulating estrogens, increased
vaginal pH, and decreased immune competence leading
to possible increased acquisition of new HPV infections
and/or reactivation of latent infections.
There were several limitations in our study. We realize
that we did not have adequate information regarding
vaginal conditions such as BV which could have been
useful in characterizing underlying causes of elevated
vaginal pH. Furthermore, this study did not include data
on female and/or male sexual behavior, an especially
important determinant of HPV prevalence in women in
Guanacaste. Therefore, we were unable to address
whether the relationship between vaginal pH and HPV
was confounded by sexual activity. Finally, we did not
measure pH and HPV frequently enough to assess the
temporal direction of any possibly causal relationship.
Thus, we are not claiming that the associations we
found suggest that elevated pH increases HPV preva-
lence. This is meant to be the report of a novel epide-
miologic association.
Conclusions
Our data suggest that elevated vaginal pH is related to
detection of HPV, particularly multiple type infections,
and LSIL in certain age groups and with detection of C.
trachomatis DNA in women aged < 25 years. Future
studies should obtain closely spaced measurements, per-
mitting a focus specifically on the temporal sequence of
HPV acquisition and increased vaginal pH, and should
include data on pH modulators such as the vaginal
microflora, chronic inflammation, and/or pre-and-peri-
menopausal hormone levels. If increased vaginal pH is
found to precede an HPV infection, this might elevate
the clinical significance of measuring vaginal pH. How-
ever, utility of this or any biomarker must be firmly
established before introduction into clinical practice. In
addition to studying vaginal pH, we anticipate that by
using high-throughput sequencing of a shared region of
bacterial ribosomes (16S ribosomal RNA) [30], we can
more precisely define altered vaginal ecosystems and
explore the associations of the cervical microbiome as a
modifier of HPV natural history in the development of
cervical precancer and cancer.
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